Michail Nikolaou
Overview
Explore the profile of Michail Nikolaou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orfanakos K, Alifieris C, Verigos E, Deligiorgi M, Verigos K, Panayiotidis M, et al.
Biomedicines
. 2024 Jan;
12(1).
PMID: 38255239
Ionizing radiation is strongly linked to direct or indirect DNA damage, as with the production of reactive oxygen species (ROS), which in turn produce DNA damage products, such as 8-hydroxy-2-deoxyguanosine...
2.
Matikas A, Kotsakis A, Perraki M, Hatzidaki D, Kalbakis K, Kontopodis E, et al.
Breast Care (Basel)
. 2022 Aug;
17(3):264-271.
PMID: 35949417
Introduction: The purpose of this study was to study the efficacy of subsequent treatment lines for metastatic breast cancer (MBC), as well as the association between radiologic objective response rate...
3.
Alexiou A, Tsagkaris C, Chatzichronis S, Koulouris A, Haranas I, Gkigkitzis I, et al.
Curr Med Chem
. 2022 Aug;
30(3):356-370.
PMID: 35927901
Even though the promising therapies against cancer are rapidly improved, the oncology patients population has seen exponential growth, placing cancer in 5th place among the ten deadliest diseases. Efficient drug...
4.
Tzovaras A, Karatrasoglou E, Talagani S, Perdikari K, Veros C, Nikolaou M
Curr Med Res Opin
. 2022 Apr;
38(8):1383.
PMID: 35369834
No abstract available.
5.
Kamposioras K, Ntellas P, Nikolaou M, Germetaki T, Gazouli I, Dadouli K, et al.
JNCI Cancer Spectr
. 2021 Dec;
5(6).
PMID: 34926989
Background: The therapeutic role of immune checkpoint inhibitors (ICIs) has represented the cutting edge of clinical research in upper gastrointestinal (GI) malignancies, with these agents now included in the armamentarium...
6.
Sagredou S, Dalezis P, Papadopoulou E, Voura M, Deligiorgi M, Nikolaou M, et al.
Pharmaceutics
. 2021 Jul;
13(6).
PMID: 34203761
Microsatellite instability (MSI), tumor mutation burden (TMB), and programmed cell death ligand-1 (PD-L1) are particularly known as immunotherapy predictive biomarkers. MSI and TMB are closely related to DNA mismatch repair...
7.
Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M
J Hepatocell Carcinoma
. 2021 May;
8:387-401.
PMID: 34012929
The last three years have seen remarkable progress in comprehending predisposing factors and upgrading our treatment arsenal concerning hepatocellular carcinoma (HCC). Until recently, there were no means to withstand the...
8.
Strati A, Nikolaou M, Georgoulias V, Lianidou E
Diagnostics (Basel)
. 2021 Apr;
11(3).
PMID: 33799422
In metastatic breast cancer (MBC) the molecular characterization of circulating tumor cells (CTCs) provides a unique tool to understand metastasis-biology and therapy-resistance. We evaluated the prognostic significance of gene expression...
9.
Koulouris A, Tsagkaris C, Nikolaou M
Toxins (Basel)
. 2021 Mar;
13(2).
PMID: 33672017
Intense research on immunotherapy has been conducted during recent years. As advances in the field have started changing the landscape of cancer therapy, it is necessary to assess the impact...
10.
Papaxoinis G, Athanasiadis A, Sgouros J, Visvikis A, Drizou M, Kontopodis E, et al.
J Oncol
. 2020 Oct;
2020:5304516.
PMID: 33014051
Background: During the last decade, significant improvement was made in systemic therapy of pancreatic adenocarcinoma (PAC). The impact of this progress in everyday clinical practice has not been fully described...